Corporate Information-arkiv

Isofol expands the number of study sites to accelerate patient recruitment in cancer study

GOTHENBURG, Sweden, August 24, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical […]

Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin

GOTHENBURG, Sweden, July 8, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

GOTHENBURG, Sweden, May 19, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the “Company”) held its annual general meeting

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

GÖTEBORG, 15 april 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) hereby invites the shareholders of Isofol Medical AB

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

GOTHENBURG, Sweden, April 15, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority

Isofol secures license rights for arfolitixorin in autism

GOTHENBURG, Sweden, March 18, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

GOTHENBURG, Sweden, 13 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) carried out a rights issue of units

Corporate Information